15. National Bioethics Advisory Commission. *Research involving persons with mental disorders that may affect their decisionmaking capacity.* Rockville, MD, 1998.
16. Department of Health Education and Welfare. Protection of human subjects. Proposed regulations on research involving those institutionalized as mentally disabled. *Fed Reg* 1978; 43:53950–53956.
17. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med* 1987; 317:141–145.
18. Weijer C. The ethical analysis of risk. *J Law Med Ethics* 2000; 28:344–361.
19. Cutler NR, Sramek JJ. Guidelines for conducting bridging studies in Alzheimer disease. *Alzheimer Dis Assoc Disord* 1998; 12:88–92.
20. Kant I. *Groundwork of the metaphysics of morals.* Cambridge: Cambridge University Press, 1998.
21. Marson DC, Earnst KS, Jamil F, et al. Consistency of physicians' legal standard and personal judgments of competency in patients with Alzheimer's disease. *J Am Geriatr Soc* 2000; 48:911–918.
22. Warren JW, Sobal J, Tenney JH, et al. Informed consent by proxy: an issue in research with elderly patients. *N Engl J Med* 1986; 315:1124–1128.
23. Sachs GA, Stocking CB, Stern R, et al. Ethical aspects of dementia research: informed consent and proxy consent. *Clin Res* 1994; 42:403–412.
24. Schulz R, O'Brien A, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. *Gerontologist* 1995; 35:771–791.
25. Grisso T, Appelbaum PS. Comparison of standards for assessing patients' capacities to make treatment decisions. *Am J Psychiatry* 1995; 152:1033–1037.
26. Appelbaum PS, Grisso T, Frank E, et al. Competence of depressed patients for consent to research. *Am J Psychiatry* 1999; 156:1380–1384.
27. Elliott C. Caring about risks: are severely depressed patients competent to consent to research? *Arch Gen Psychiatry* 1997; 54:113–116.
28. Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. *Lancet* 2000; 356:1326–1327.
29. Ganzini L, Lee M, Heintz R. The effect of depression treatment on elderly patients' preferences for life-sustaining medical therapy. *Am J Psychiatry* 1994; 151:1631–1636.
30. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer's disease. *J Gerontol B Psychol Sci Soc Sci* 2000; 55B:2–13.
31. Karlawish JHT, Klocinski J, Merz JF, et al. Caregivers' preferences for the treatment of patients with Alzheimer's disease. *Neurology* 2000; 55:1008–1014.
32. Karlawish JHT, Casarett D, Klocinksi J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? *Neurology* 2001; 56:789–792.
33. Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. *IRB Rev Hum Subj Res* 1987; 9:7–10.
34. Casarett D, Karlawish JHT, Sankar P, et al. Should open label extension studies be required in the design of clinical drug trials? *IRB Rev Hum Subj Res* 2001; in press.
35. Karlawish JHT, Lantos J. Community equipoise and the architecture of clinical research. *Camb Q Healthc Ethics* 1997; 6:385–396.
36. Karlawish JHT. Permissible risk and acceptable benefit: the ethics of research involving the cognitively impaired. *FORUM* 1997; 7:277–285.
37. Post SG, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. *J Am Geriatr Soc* 1998; 46: 784–787.
38. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: patient and caregiver reports. *J Ment Health Aging* 1999; 5:21–32.
39. Logsdon RG, Gibbons LE, Teri L, McCurry SM. Quality of life in Alzheimer's disease: longitudinal perspectives [abstract]. *Gerontologist* 1999; 39:164.
40. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. *Neurology* 1997; 49:38–43.

Index

Volume 14, 2001

Author Index

Abashidze A, 17
Alessi N, 88
Argüelles S, 91
Argüelles T, 91

Barbas NR, 167, 199
Bekkelund SI, 7
Bell S, 33
Bellavance F, 37
Bernabei R, 21
Blennow K, 109
Brown E, 125

Camicioli RM, 1
Casarett D, 222
Cattel C, 21
Cesari M, 21
Cohen RA, 33
Cole MG, 37
Connell CM, 179
Cummings JL, 101
Cyrus PA, 101

Darkins A, 80
Derrer DS, 1
Du A-T, 145

Edman Å, 140
Eisdorfer C, 91
Elie LM, 37
Engberg R, 130
Engberg S, 130

Ferretti L, 52
Foster NL, 167, 188

Gallagher-Thompson D, 115
Gallant MP, 179
Gambassi G, 21
Gibbons L, 52
Gordon N, 33
Gottfries C-G, 109
Gottfries J, 109
Grant JE, 125
Grob P, 63

Hedera P, 213
Heeren TJ, 11
Hicks L, 120
Hogh P, 42
Hovanec L, 76
Howieson DB, 1
Hsu Y-Y, 145

Janevic MR, 179
Jimerson N, 17
Johnston D, 66, 72
Jones BN III, 59, 66, 72, 76
Jorgensen OS, 42

Kahn RS, 11
Karlawish JHT, 222
Kaye JA, 1
Kim SW, 125
Kjaer KH, 42
Knudsen GM, 42
Kraemer HC, 115
Kujala I, 7

Lalonde FM, 120
Lampe IK, 11
Landi F, 21
Lattanzio F, 21
Lehmann MW, 109
Loewenstein DA, 91
Logsdon R, 52
Lyketsos CG, 76

Mahnfeldt M, 140
Mansour A, 37
Masterman D, 101
McCall WV, 66
McCurry SM, 52
McCusker J, 37
McDowell BJ, 130
Mittal D, 17
Moser D, 33
Mueller EA, 1
Murman DL, 168
Murphy GM Jr, 115

15. National Bioethics Advisory Commission. *Research involving persons with mental disorders that may affect their decisionmaking capacity.* Rockville, MD, 1998.
16. Department of Health Education and Welfare. Protection of human subjects. Proposed regulations on research involving those institutionalized as mentally disabled. *Fed Reg* 1978; 43:53950–53956.
17. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med* 1987; 317:141–145.
18. Weijer C. The ethical analysis of risk. *J Law Med Ethics* 2000; 28:344–361.
19. Cutler NR, Sramek JJ. Guidelines for conducting bridging studies in Alzheimer disease. *Alzheimer Dis Assoc Disord* 1998; 12:88–92.
20. Kant I. *Groundwork of the metaphysics of morals.* Cambridge: Cambridge University Press, 1998.
21. Marson DC, Earnst KS, Jamil F, et al. Consistency of physicians' legal standard and personal judgments of competency in patients with Alzheimer's disease. *J Am Geriatr Soc* 2000; 48:911–918.
22. Warren JW, Sobal J, Tenney JH, et al. Informed consent by proxy: an issue in research with elderly patients. *N Engl J Med* 1986; 315:1124–1128.
23. Sachs GA, Stocking CB, Stern R, et al. Ethical aspects of dementia research: informed consent and proxy consent. *Clin Res* 1994; 42:403–412.
24. Schulz R, O'Brien A, Bookwala J, Fleissner K. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. *Gerontologist* 1995; 35:771–791.
25. Grisso T, Appelbaum PS. Comparison of standards for assessing patients' capacities to make treatment decisions. *Am J Psychiatry* 1995; 152:1033–1037.
26. Appelbaum PS, Grisso T, Frank E, et al. Competence of depressed patients for consent to research. *Am J Psychiatry* 1999; 156:1380–1384.
27. Elliott C. Caring about risks: are severely depressed patients competent to consent to research? *Arch Gen Psychiatry* 1997; 54:113–116.
28. Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. *Lancet* 2000; 356:1326–1327.
29. Ganzini L, Lee M, Heintz R. The effect of depression treatment on elderly patients' preferences for life-sustaining medical therapy. *Am J Psychiatry* 1994; 151:1631–1636.
30. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer's disease. *J Gerontol B Psychol Sci Soc Sci* 2000; 55B:2–13.
31. Karlawish JHT, Klocinski J, Merz JF, et al. Caregivers' preferences for the treatment of patients with Alzheimer's disease. *Neurology* 2000; 55:1008–1014.
32. Karlawish JHT, Casarett D, Klocinksi J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? *Neurology* 2001; 56:789–792.
33. Freedman B. Scientific value and validity as ethical requirements for research: a proposed explication. *IRB Rev Hum Subj Res* 1987; 9:7–10.
34. Casarett D, Karlawish JHT, Sankar P, et al. Should open label extension studies be required in the design of clinical drug trials? *IRB Rev Hum Subj Res* 2001; in press.
35. Karlawish JHT, Lantos J. Community equipoise and the architecture of clinical research. *Camb Q Healthc Ethics* 1997; 6:385–396.
36. Karlawish JHT. Permissible risk and acceptable benefit: the ethics of research involving the cognitively impaired. *FORUM* 1997; 7:277–285.
37. Post SG, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. *J Am Geriatr Soc* 1998; 46: 784–787.
38. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: patient and caregiver reports. *J Ment Health Aging* 1999; 5:21–32.
39. Logsdon RG, Gibbons LE, Teri L, McCurry SM. Quality of life in Alzheimer's disease: longitudinal perspectives [abstract]. *Gerontologist* 1999; 39:164.
40. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. *Neurology* 1997; 49:38–43.

Index

Volume 14, 2001

Author Index

Abashidze A, 17
Alessi N, 88
Argüelles S, 91
Argüelles T, 91

Barbas NR, 167, 199
Bekkelund SI, 7
Bell S, 33
Bellavance F, 37
Bernabei R, 21
Blennow K, 109
Brown E, 125

Camicioli RM, 1
Casarett D, 222
Cattel C, 21
Cesari M, 21
Cohen RA, 33
Cole MG, 37
Connell CM, 179
Cummings JL, 101
Cyrus PA, 101

Darkins A, 80
Derrer DS, 1
Du A-T, 145

Edman Å, 140
Eisdorfer C, 91
Elie LM, 37
Engberg R, 130
Engberg S, 130

Ferretti L, 52
Foster NL, 167, 188

Gallagher-Thompson D, 115
Gallant MP, 179
Gambassi G, 21
Gibbons L, 52
Gordon N, 33
Gottfries C-G, 109
Gottfries J, 109
Grant JE, 125
Grob P, 63

Hedera P, 213
Heeren TJ, 11
Hicks L, 120
Hogh P, 42
Hovanec L, 76
Howieson DB, 1
Hsu Y-Y, 145

Janevic MR, 179
Jimerson N, 17
Johnston D, 66, 72
Jones BN III, 59, 66, 72, 76
Jorgensen OS, 42

Kahn RS, 11
Karlawish JHT, 222
Kaye JA, 1
Kim SW, 125
Kjaer KH, 42
Knudsen GM, 42
Kraemer HC, 115
Kujala I, 7

Lalonde FM, 120
Lampe IK, 11
Landi F, 21
Lattanzio F, 21
Lehmann MW, 109
Loewenstein DA, 91
Logsdon R, 52
Lyketsos CG, 76

Mahnfeldt M, 140
Mansour A, 37
Masterman D, 101
McCall WV, 66
McCurry SM, 52
McCusker J, 37
McDowell BJ, 130
Mittal D, 17
Moser D, 33
Mueller EA, 1
Murman DL, 168
Murphy GM Jr, 115

Myslobodsky M, 120
Nadel A, 101
O'Hara R, 115
Onder G, 21
Ott BR, 33
Paul RH, 33
Paulson OB, 42
Raskin A, 63
Reboussin B, 66
Regland B, 109
Reynolds CF, 130
Roques C, 76
Rosenvinge B, 7
Ruskin PE, 59, 63
Russo A, 21
Sayles D, 63
Schuff N, 145
Sereika S, 130
Sexton G, 1
Simmons A, 115
Sommer BR, 99
Stone W, 33
Teri L, 52
Torres R, 17
Waldemar G, 42
Wallin A, 140
Weber E, 130
Weiner MW, 145
Weintraub D, 28, 63
Wilde EA, 199
Zawacki T, 33

Subject Index

Activities of Daily Living, 130-138
Alzheimer's disease, 7-10, 42-57, 91-97, 101-107, 115-118, 145-146, 154-156, 168-176, 192-194, 213-220, 222-227
Amygdala, 147-148
Anhedonia, 11-16
Antipsychotics, 99-100
Anxiety disorder, 52-57
Apathy, 11-16
Apolipoprotein E, 42-50, 115-118
Audiovisual telecommunication, 63-65
Behavior, 101-107, 115-118
Blood flow, 42-50
Brain, 33-35, 146-149
Brief Psychiatric Rating Scale, 63-65, 66-70
Caregivers, 91-97, 115-118, 167-176, 179-185, 190-191, 224-225
Cerebral blood flow, 42-50
Cognitive function, 1-5, 17-26, 109-114, 150
Community-living older adults, 21-26
Companion animals, 183
Competency, 199-210
Comprehensive Psychopathological Rating Scale, 11-16
Copper Ridge long-term care facility, 76-79
Corpus callosum, 148
Cortex, 148
Decision making, 200-203
Dementia, 1-5, 7-10, 33-35, 109-114, 145-158, 167-176, 179-185, 188-196, 199-210, 213-220, 222-227
Dementia Rating Scale, 33-35
Depression, 28-31, 37-40, 63-65, 91-97, 115-118, 130-138
Diagnostic and Statistical Manual of Mental Disorders, 52-57, 125-129
Direct Assessment of Functional Status, 91-97
Driving, 203-206
Entorhinal cortex, 148
Ethics, 167, 200, 213-220, 222-227
Extrapyramidal side effects, 99-100
Frontotemporal dementia, 150-151, 156-157
Gambling disorder, 125-129
Genetic testing, 213-220
Geriatric Depression Scale, 63-65, 115-118, 130-138
Health care services, 80-85
Hippocampus, 147, 149
Homebound adults, 130-138
Huntington's disease, 152-153, 157
Hyperintensity, 33-35
Idiopathic Parkinson's disease, 151-152
Incontinence, 130-138
Independent living, 206-210
Informed consent, 223-225
Instrumental Activities of Daily Living, 130-138
Lewy bodies, 151
Long-term care facility, 76-79
Magnetic resonance imaging, 145-154
Magnetic resonance spectroscopy, 154-158
Managed care, 168-176
Mattis Dementia Rating Scale, 33-35
Medicaid, 168-176
Medical decision making, 200-203
Medicare, 168-176
Memory, 1-5, 115-118
Memory and Behavior Problem Checklist, 115-118
Metabolism, 109-114
Metrifonate, 101-107
Mini-Mental State Examination, 1-5, 11-16, 42-50, 63-65, 109-118, 130-138
Multicomponent interventions, 184
Neurobehavioral Cognitive Status Examination, 1-5
Neurodegenerative dementia, 156
Neuroimaging, 33-35
Neuropsychiatric Inventory, 101-107
Nortriptyline, 28-31
Nursing homes, 63-65, 72-79
One-carbon metabolism, 109-114
Parahippocampal gyrus, 147-148
Parkinson's disease, 99-100, 120-123, 151-152, 157
Pathologic gambling disorder, 125-129
Performance-Based Toileting Assessment, 130-138
Pets, 183
Physicians, 188-196, 201, 202, 203, 207
Post-stroke depression, 37-40
Post-traumatic stress disorder, 17-20
Program of All-Inclusive Care for the Elderly, 171
Psychiatric admissions, 76-79
Psychiatric symptoms, 7-10
Psychiatry, 59-75, 88-90
Psychomotor retardation, 11-16
Psychosis, 99-100
Quetiapine, 99-100
Relaxometry, 149-150
Respite care, 184
Retardation, 11-16
Rural nursing facility, 72-75
Serotonin reuptake inhibitors, 28-31
Single photon emission computed tomography, 42-50
Snaith-Hamilton Pleasure Scale, 11-16
Stepwise Comparative Status Analysis, 140-144
Stress, 17-20, 115-118
Stroke, 37-40
Subcortical hyperintensity, 33-35
Suicide, 120-123
Support groups, 182, 183
Telecommunications, 59-65
Telemedicine, 59-62, 76-85
Telemental health care services, 80-85
Telepsychiatry, 59-75, 88-90
Urinary incontinence, 130-138
Vascular dementia, 7-10, 33-35, 109-114, 153-154, 158
Videoconferencing, 59-62, 66-70
Wechsler Memory Scale, 1-5
White matter, 149
Whole brain volume, 33-35, 146-147